Skip to content
The Policy VaultThe Policy Vault

Hetlioz (tasimelteon)Highmark

Nighttime Sleep Disturbances in Smith-Magenis Syndrome (SMS)

Initial criteria

  • age ≥ 16 years
  • diagnosis of Smith-Magenis Syndrome confirmed by deletion of chromosome 17p11.2 OR variant in RAI1 gene
  • member experiencing nighttime sleep disturbances including difficulty falling asleep, shortened sleep cycles, inability to enter REM sleep, or frequent awakening during the night and early in the morning

Reauthorization criteria

  • prescriber attests member has experienced an increase in total nighttime sleep time OR increase in sleep quality

Approval duration

12 months